IL1B and myocardial infarction: The landmark CANTOS trial demonstrated that the IL-1β monoclonal antibody canakinumab reduced recurrent major adverse cardiovascular events in post-myocardial infarction (MI) patients (hazard ratio (HR): 0.85; 95% confidence interval (CI): 0.74–0.98; P = 0.021) (1); however, prohibitive costs and increased infection risk precluded its broad application.